moatshark My

All holdings

Merck & Co.

MRK

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
10
In their latest 13F (Q3 2026)
See who
Value held
$2.0bn
Combined value at quarter end
Last quarter
1 bought
7 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q3 ’26 end
$145.31
+13.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-12.4%Q4 ’24
-9.8%Q1 ’25
-11.8%Q2 ’25
+6.0%Q3 ’25
+25.4%Q4 ’25
+14.3%Q1 ’26
+6.8%Q2 ’26
+13.1%Q3 ’26
Q4 ’24: -12.4%; Q1 ’25: -9.8%; Q2 ’25: -11.8%; Q3 ’25: +6.0%; Q4 ’25: +25.4%; Q1 ’26: +14.3%; Q2 ’26: +6.8%; Q3 ’26: +13.1%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

9Q4 ’23
9Q1 ’24
9Q2 ’24
10Q3 ’24
10Q4 ’24
10Q1 ’25
9Q2 ’25
9Q3 ’25
9Q4 ’25
10Q1 ’26
10Q2 ’26
2Q3 ’26
Q4 ’23: 9; Q1 ’24: 9; Q2 ’24: 9; Q3 ’24: 10; Q4 ’24: 10; Q1 ’25: 10; Q2 ’25: 9; Q3 ’25: 9; Q4 ’25: 9; Q1 ’26: 10; Q2 ’26: 10; Q3 ’26: 2

Counts the managers on this site whose 13F for that quarter includes Merck & Co..

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Merck & Co.
Smead Capital Management7.1%$335m$335mTrimmed -1.2%49 qtrs
Kahn Brothers4.4%$28.0m$28.0mTrimmed -4.0%18 qtrs
Harris Associates (Oakmark)2.1%$1.6bn$1.6bnTrimmed -2.4%8 qtrs
Fairfax Financial Holdings0.8%$22.2m$22.2mUnchanged23 qtrs
Semper Augustus0.7%$5.7m$5.7mUnchanged53 qtrs
Mairs & Power0.1%$6.6m$6.6mAdded +2.3%53 qtrs
Horizon Kinetics0.0%$3.6m$3.6mTrimmed -0.8%30 qtrs
Matrix Asset Advisors0.0%$236k$236kTrimmed -3.0%54 qtrs
Dodge & Cox0.0%$17.4m$17.4mTrimmed -0.2%53 qtrs
Gardner Russo & Quinn0.0%$211k$211kTrimmed -23%2 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Merck & Co.
Bought or soldFiling
13 Aug 2026Guindo ChirfiEVP, Access, Policy & Comms▼ Sold10,000$135.00$1.4mForm 4
12 Aug 2026Zachary JenniferEVP, General Counsel▼ Sold80,315$133.46$10.7mForm 4
12 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold11,099$131.61$1.5mForm 4
12 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold600$132.04$79kForm 4
11 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold7,410$131.33$973kForm 4
11 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold5,427$132.35$718kForm 4
10 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold20,784$130.43$2.7mForm 4
6 Aug 2026Guindo ChirfiEVP, Access, Policy & Comms▼ Sold15,000$131.00$2.0mForm 4
6 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold4,945$130.23$644kForm 4
6 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold805$131.02$105kForm 4
6 Aug 2026Deluca Richard R.EVP&Pres, Merck Animal Heallth▼ Sold300$131.02$39kForm 4
5 Aug 2026Williams David MichaelEVP,Chief Info&Digital Officer▼ Sold34,705$128.77$4.5mForm 4
5 Aug 2026Williams David MichaelEVP,Chief Info&Digital Officer▼ Sold13,542$128.77$1.7mForm 4
5 Aug 2026Maraldo David R.EVP & Pres. MMD▼ Sold9,709$128.72$1.2mForm 4
5 Aug 2026Maraldo David R.EVP & Pres. MMD▼ Sold6,311$128.72$812kForm 4
5 Aug 2026Williams David MichaelEVP,Chief Info&Digital Officer▼ Sold4,600$128.77$592kForm 4
5 Aug 2026Maraldo David R.EVP & Pres. MMD▼ Sold2,686$128.72$346kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
New Jersey
Financial year ends
31 December
Shares outstanding
2.47bn at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

2013
2015
$40bn2017
$39bn2019
$49bn2021
$60bn2023
$65bn2025
2013: not held; 2014: not held; 2015: not held; 2016: $40bn; 2017: $40bn; 2018: $42bn; 2019: $39bn; 2020: $42bn; 2021: $49bn; 2022: $59bn; 2023: $60bn; 2024: $64bn; 2025: $65bn
Merck & Co. revenue and net income by year
YearRevenueNet income
2025$65bn$18bn
2024$64bn$17bn
2023$60bn$365m
2022$59bn$15bn
2021$49bn$12bn
2020$42bn$7.1bn
2019$39bn$9.8bn
2018$42bn$6.2bn
2017$40bn$2.4bn
2016$40bn$3.9bn
2015–$4.4bn
2014–$12bn
2013–$4.4bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Merck & Co., from their latest N-PORT filings.

Funds holding Merck & Co.
Smead Value FundSmead Capital Management5.9%$230m29 May 2026